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Amyloid precursor protein (APP) is a key player in Alzheimer’s disease (AD). The Ab fragments of APP are the
major constituent of AD-associated amyloid plaques, and mutations or duplications of the gene coding for
APP can cause familial AD. Here we review the roles of APP in neuronal development, signaling, intracellular
transport, and other aspects of neuronal homeostasis. We suggest that APP acts as a signaling nexus that
transduces information about a range of extracellular conditions, including neuronal damage, to induction
of intracellular signaling events. Subtle disruptions of APP signaling functions may be major contributors
to AD-causing neuronal dysfunction.Introduction
Since its discovery in 1987, functions of the amyloid precursor
protein (APP) and its cleavage products have been subject to
intense investigation. These investigations were initially stimu-
lated by the finding that 40–42 amino acid peptide fragments
of APP called Ab are abundant in amyloid plaques in the brains
of people with Alzheimer’s disease (AD). Thus, much AD- and
APP-related research has focused on the amyloidogenic proper-
ties and toxicity of the Ab peptide, with less regard for the normal
cell biological roles of APP and its other cleavage products.
However, the discovery of APP mutations and duplications in fa-
milial AD (FAD) led to many investigations of APP function (Rove-
let-Lecrux et al., 2006; Sleegers et al., 2006). In addition, FAD
mutations in the presenilin genes, which encode the catalytic
subunit of the APP processing g-secretase enzyme, further un-
derscore the functional importance of APP cleavage products.
Understanding the extent to which APP functions are modulated
by mutations (FAD) and natural genetic variation (sporadic AD)
and whether, and if so, how, these contribute to AD pathology
is a key challenge.
Herewe review studies of APP function that focus on twomajor
questions. First, in which cellular/neuronal functions does APP
have a role?Second,doalterations in thenormal cellular/neuronal
functions of APPplay a significant role in AD?We reviewobserva-
tions that implicateAPP inneuronal development, signaling, intra-
cellular transport, and other aspects of cellular homeostasis and
highlight the compartmentalized generation of APP proteolytic
products by secretases and the unique potential roles played by
different APP fragments. Finally, we discuss how genetic alter-
ations in the APP gene could contribute to AD by altering frag-
ments other than Ab. We suggest that while studies of APP func-
tion that go beyondoverexpression are comparatively limited, the
available data point to a role for APP as a generalized signaling
nexus that transduces information about a range of extracellular
conditions to induction of intracellular signaling events.
Clues from Evolution: Structure of APP and Its Relatives
across Species
Human APP is a member of the APP family of proteins, which
also includes APP-like protein 1 and 2 (APLP1 and APLP2)502 Developmental Cell 32, February 23, 2015 ª2015 Elsevier Inc.(Figure 1). This family is conserved across a variety of species,
and members can be found in invertebrates, including
C. elegans (APP-like 1, APL-1) and D. melanogaster (APP-like,
APPL). Prokaryotes, plants, and yeasts do not appear to
possess members of the APP family of proteins. The evolu-
tionary appearance of the APP family of proteins therefore
seems to coincide with the evolution of the earliest nervous sys-
tems with functioning synapses (Shariati and De Strooper, 2013)
but also coincides with other events such as the appearance of
lipoprotein receptors (Dieckmann et al., 2010). Based on direct
sequence comparisons of the three human APP family mem-
bers, APLP1 may be the closest human homolog of the inverte-
brate APP-like proteins (APL-1 and APPL) (Joshi et al., 2009);
however, evolutionary relationships are difficult to interpret
as the APP family of genes has undergone multiple duplica-
tion events and development of different splice variants. For
example, birds have only two homologs (APP and APLP2), and
amphibians and fish have four members. The mammalian APP
gene contains 18 exons and undergoes several alternative-
splicing events. APP695, the major brain isoform and the first
cloned APP splice variant (Kang et al., 1987) excludes exon 7
(KPI domain) and 8 (OX-2 homology domain) (Figure 1). While
APP expression and function have beenmost intensively studied
for this brain-specific variant, other APP splice variants are also
expressed inmany other tissues such as the thymus, heart, mus-
cle, lung, kidney, adipose tissue, liver, spleen, skin, and intestine
(Puig and Combs, 2013). These include APP770, APP751 (lack-
ing exon8), APP714, and the shorter APP639 (expressed in fetal
tissue and adult liver) (Golde et al., 1990; Nalivaeva and Turner,
2013; Tang et al., 2003). The leukocyte-derived APP (L-APP)
splice variants (APP677, APP696, APP733, APP752) lack exon
15 and are expressed at high levels in leukocytes and can be
upregulated in activated astrocytes and microglia (Beyreuther
et al., 1993).
APP, APLP1, and APLP2 are all single-pass transmembrane
proteins with a small intracellular C-terminal domain and a large
N-terminal extracellular region reminiscent of a transmembrane
receptor protein (Figure 1). APP is the only family member
with an Ab peptide domain. Both APP C- and N-terminal do-
mains have been implicated in numerous cellular processes (as
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Figure 1. Domain Organization and Tissue
Expression of the APP Family Proteins
(Left) A schematic diagram depicting major do-
mains in the longest APP isoform (APP770). The
APP ectodomain (671AA) is much larger than the
transmembrane and intracellular domain regions
of APP. The PM is in gray. (Top right) Schematic
depiction of major domains in the APP-protein
family members APLP1 and APLP2 and two major
APP splice variants (APP695 and APP770). The
predominant tissue expression profile for these
proteins is shown below. (Bottom right) Genetic
interactions of the different APP family proteins in
mice.
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unprocessed APP holoprotein, in specific cleavage fragments,
or in both. The short unstructured C-terminal domain has no
obvious homology to other types of proteins but is conserved
among APP, APLP1, and APLP2 and serves as a site for
numerous functional protein interactions (discussed below, C
terminus alignment in Figure 2). Recent biochemical and struc-
tural work suggests that the C terminus also undergoes interac-
tions with the lipid bilayer with the extreme hydrophobic-end
interacting directly with the membrane (Barrett et al., 2012).
The N terminus is more divergent between APP family members
and APP splice variants. The N terminus of APLP2 and APP770
(both expressed in multiple organs and tissues) contain two
dimerization domains (E1 and E2), an acidic domain (Ac), a Ku-
nitz protease inhibitor (KPI) region, and an OX-2 domain, while
APP695 and APLP1 (expressed predominantly in brain) both
lack the KPI and OX-2 domains (Figure 1). Within the N terminus,
the E1 and E2 domains can bind heparin, zinc, and copper
and mediate formation of homodimers and heterodimers with
different family members (Ott and Bullock, 2001; Sarasa et al.,
2000). APP expression in developing rats and mice can be
detected very early in embryogenesis (detected at embryonicDevelopmental Cell 32,day 9 for rat and at the gastrulation stage
for mice) (Ott and Bullock, 2001; Sarasa
et al., 2000), suggesting an important
role for APP in development.
Possible Functions of APP Family
Members in Brain Development
and Maintenance
Important clues to APP function in devel-
opment have come from genetic ana-
lyses in organisms that have only a single
APP family member. For example, in the
worm, Caenorhabditis elegans, APL-1
knockout is lethal due to a molting defect
(Hornsten et al., 2007; Wiese et al., 2010).
APPL knockout Drosophila are viable but
have subtle behavioral defects (including
conditional learning defects) (Luo et al.,
1992) and defects in maintenance of syn-
aptic boutons at the neuromuscular junc-
tion (NMJ) (Torroja et al., 1999b) and are
more vulnerable to brain injury (Leyssen
et al., 2005). APPL also modulates the
Wnt-planar cell polarity (PCP) pathway required for axonal
outgrowth during neuronal development (Soldano et al., 2013).
Finally, deletion mutations of the Drosophila APPL gene, or ani-
mals overexpressing either APPL, human APP, or the C terminus
of humanAPLP2 exhibit Ab-independent defects in axonal trans-
port mediated by the conserved cytoplasmic C terminus (Gold-
stein, 2012; Gunawardena and Goldstein, 2001; Rusu et al.,
2007; Torroja et al., 1999a). These defects exhibit strong genetic
interactions with motor proteins and interactors such as JIP1
(reviewed in Goldstein, 2012).
While the data in invertebrates argue strongly for functions of
APP and its relatives in axonal transport and other neuronal
signaling functions, possibly including long-range signaling as
a consequence of neuronal damage, it is unclear whether the
single worm and fly APP-like proteins are homologs of APLP1,
APLP2, or APP. The zebrafish is in this respect more homolo-
gous to humans, as it has APP proteins in addition to APLP1
and APLP2. Genetic analyses in zebrafish reveal that APP is
required for convergent-extension during embryogenesis, the
process by which the tissue of an embryo is restructured to
converge along one axis and extend along a perpendicular
axis by cellular movement (Joshi et al., 2009).February 23, 2015 ª2015 Elsevier Inc. 503
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Figure 2. Interactions at the APP C Terminus
(A) Depicted is the C99 fragment of APPwith pathogenicmutations in red, protectivemutations in purple, andmutationswith unknownpathogenicity in green. The
figure depicts different phosphorylation sites in the intracellular domain of APP as well as the caspase-cleavage and isomerization site. In green is the domain
involved in Pin1 and Go binding, while in yellow and red are, respectively, the YENPTY and YKFFE domains required for binding to other interaction proteins.
Binding of many of these proteins has been shown to be phosphorylation dependent. Numbering is based on APP770. The table depicts APP-dependent cellular
processes in which the CTF-interacting proteins are involved.
(B) Alignment of the intracellular C-terminal tails of APP, APLP1, and APLP2 showing high sequence homology between the members of this family. APLP1 is
most divergent, as it does not have the Pin1 binding motif and has a change of charge from positive (K) to negative (E) flanking the domain involved in G0-protein
binding.
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come from genetic analyses of mice. For example, mice lacking
any one APP family member are viable and fertile with seemingly
minor defects. APP knockout mice are viable, but have reduced
body weight, reduced locomotor activity, disturbed forelimb
strength, and gliosis. In addition, these mice have altered long-
term potentiation responses, altered performance in the Morris
water maze (Dawson et al., 1999; Seabrook et al., 1999; Zheng
et al., 1995), reduced brain weight (Magara et al., 1999), axonal
growth/white matter defects (Magara et al., 1999), and axonal
transport defects detected by more than one method or lab
(Goldstein, 2012; Kamal et al., 2001; Smith et al., 2007, 2010).
These relatively subtle phenotypes could indicate that other
APP family members may compensate for the loss of APP
(Zheng and Koo, 2006). Consistent with this view, APLP1 and
APLP2 single knockouts are also viable (von Koch et al., 1997),504 Developmental Cell 32, February 23, 2015 ª2015 Elsevier Inc.whereas double knockouts for APP and APLP2 or APLP1 and
APLP2 die early after birth (Figure 1) (Heber et al., 2000). This
finding could indicate functional redundancy where APLP2 can
take over for both APP and APLP1 functions, whereas APP or
APLP1 alone cannot compensate for the loss of the other two
family members. Although the functions of APP, APLP1, and
APLP2 may substantially overlap, it remains formally possible
that APP paralogues have unrelated nonredundant functions
where the net effect of the loss of different pathways leads to
lethality in double-knockout mice (Shariati and De Strooper,
2013). Relevant in this context is the observation that APLP1
and APLP2 levels are not upregulated in APP knockout mice
(Zheng et al., 1995); APP, APLP1, and APLP2 have different
tissue distributions, and proteins that interact within the ectodo-
mains of APP, APLP1, and APLP2 overlap only modestly (Bai
et al., 2008).
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the mouse where APP has a role in neuronal migration in early
embryogenesis. During embryogenesis, neuronal precursor
cells migrate from the ventricular zone into the cortical plate,
and this process is impaired when APP levels are reduced in
the cortex (Young-Pearse et al., 2007). Migration defects caused
by APP loss can be rescued by overexpression of human
APP695, APP751, mutant APP (Swedish and Indiana) but not
by truncated APP constructs. In particular, a targeted mutation
in the YENPTY motif located in the intracellular domain of
APP and involved in the interaction of APP with other proteins
such as FE65 and DAB1 (Figure 2) abrogates the rescue
effect of full-length APP in line with the observation that DAB1
and FE65 (Sabo et al., 2001) are also required for migration.
Other intracellular proteins such as disrupted-in-schizophrenia
1 (DISC1) (Young-Pearse et al., 2010) and the heterotrimeric G
protein Go (Ramaker et al., 2013) may also interact with APP to
regulate neuronal migration. In this regard, migration ordinarily
depends on linking interactions with the extracellular matrix to
the cytoskeleton and motor proteins. One speculation is that
APP might couple cytoskeletal motors and filaments inside the
cell (discussed below) to binding of extracellular matrix proteins
such as collagen (Beher et al., 1996), laminin (Beher et al., 1996),
and heparin sulfate proteoglycans (Ca´ceres and Brandan, 1997).
Recently, an interaction of APP and the secreted glycoproteins
of the Pancortin family was also identified (Rice et al., 2012). Pan-
cortins are highly expressed in the developing brain where they
regulate neuronal precursor cell migration into the cortical plate
(Rice et al., 2012) and thus might act as extracellular ligands that
mediate cell migration via APP. In a similar manner, the secreted
neural migration factors Reelin and F-spondin—both required
for neuronal migration—interact with APP possibly to regulate
migration (Ho and Su¨dhof, 2004; Hoe et al., 2009).
The role of APP in mammalian development persists after
birth, as APP levels peak in the second postnatal week, coin-
ciding with the timing of brain maturation and completion of syn-
aptic connections (Lo¨ffler and Huber, 1992), suggesting a role for
APP in synapse formation or maintenance. Indeed, APP can be
found at the synapse, where its processing can be regulated
by neuronal activity (Kamenetz et al., 2003). In fact, APP
knockout mice have an altered long-term potentiation response
(Dawson et al., 1999), reduced brain mass (Magara et al., 1999),
and reduced spine numbers (Tyan et al., 2012), while APP over-
expression in transgenic mice increases spine density (Lee et al.,
2010). In apparent contradiction to these findings, cultured neu-
rons from APP knockout mice show enhanced amplitudes of
excitatory postsynaptic potential and increased synapse forma-
tion, indicating that the role of APP at the synapse is not under-
stood in full at the moment (Priller et al., 2006). APP knockout
mice also display decreased locomotor activity and forelimb
strength, pointing to a possible role for APP at the NMJ (Zheng
et al., 1995). The mechanism of APP function at the NMJ is not
well understood, but could act at least in part through LDL recep-
tor-related protein 4 (LRP4) (Choi et al., 2013). LRP4 is a receptor
for agrin (a regulator of synaptogenesis), which is required for
normal NMJ formation (Yumoto et al., 2012). Interestingly, in
this context, agrin fragment levels are regulated by g-secretase
control of neurotrypsin expression (Almenar-Queralt et al., 2013).
APP, agrin, and LRP4 interact and are capable of activatingmus-cle-specific tyrosine kinase (MuSK) triggering acetylcholine re-
ceptor clustering and thereby shaping NMJ function, indicating
that APP has an important role in the formation or maintenance
of the NMJ (Choi et al., 2013).
Cholesterol is also required for synaptogenesis (Mauch et al.,
2001), and while during development neurons can produce their
own cholesterol, neurons in the adult brain are thought to rely on
cholesterol derived from internalized lipoproteins (Pfrieger and
Ungerer, 2011). One intriguing possibility is that APP controls li-
poprotein metabolism via interactions with LRPs such as LDLR-
related protein 1 (LRP1) (Kounnas et al., 1995; Trommsdorff
et al., 1998), LRP1B (Cam et al., 2004), Megalin (or LRP2) (Al-
vira-Botero et al., 2010), MEGF7 (or LRP4) (Choi et al., 2013),
very low-density lipoprotein receptor (VLDLR) (Dumanis et al.,
2012), Apoer2 (or LRP8) (Hoe et al., 2005), SorlA (or SORL1/
LR11) (Andersen et al., 2005), and LRAD3 (Ranganathan et al.,
2011). Many of the LRPs are also g-secretase substrates (Haa-
pasalo and Kovacs, 2011), and LRPs themselves could regulate
APP trafficking and processing (Marzolo and Bu, 2009), indi-
cating that APP might couple synaptic activity with lipid flux.
An exciting new finding is that APP can also bind cholesterol
directly (Barrett et al., 2012; Beel et al., 2008) such that APP frag-
mentsmight be able to regulate genes in the cholesterol pathway
directly (Grimm et al., 2005; Pierrot et al., 2013; Wang et al.,
2014). Since the generation of these APP fragments is regulated
by neuronal activity (Kamenetz et al., 2003), APP and APP frag-
ments might thus regulate lipid intake and distribution to support
membrane reorganization during synaptic activity. The genera-
tion of APP fragments is discussed below.
APP Trafficking and Processing: A Complex Itinerary
The finding that APP undergoes extensive and complex proteo-
lytic processing suggests that APP functions may be carried out
by proteolytic fragments. Enzymes called secretases cleave APP
in different positions to generate smaller APP fragments that
may all be potently bioactive (Figure 3). Generation of these
fragments is compartmentalized with processing of full-length
APP and APP intermediate-proteolytic fragments occurring in
different organelles. As the site of generation may determine
function, APP trafficking and compartmentalized cleavage are
under intense investigation (reviewed in Haass et al., 2012; Ra-
jendran and Annaert, 2012). APP is ordinarily synthesized in as-
sociation with the ER and transported to the plasma membrane
(PM) via the secretory pathway. At the PM, APP is cleaved
by a-secretase (Sisodia, 1992) releasing soluble APPa (sAPPa)
in the extracellular environment (a-cleavage occurs in the Ab
domain of APP preventing generation of Ab and is therefore
referred to as non-amyloidogenic). The b-site APP-cleaving
enzyme 1 (BACE-1) is the major b-secretase and can cleave
APP in early endosomes (EEs) (Rajendran et al., 2006; Sannerud
et al., 2011), possibly depending on acidification during matura-
tion of these organelles. APP might be targeted to sites of endo-
cytosis by associating with lipid-domains (lipid-rafts) that could
also sequester APP away from the non-raft-associated a-secre-
tase (Ehehalt et al., 2003). Although BACE1 is also enriched in
lipid rafts, BACE1 and APP can be found in separate vesicle
pools that could come together in the somatodendritic compart-
ment upon neuronal activity (Das et al., 2013). BACE1 and APP
can also be separately internalized from the PM, in which caseDevelopmental Cell 32, February 23, 2015 ª2015 Elsevier Inc. 505
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Figure 3. APP Proteolytic Products and Intracellular Trafficking of APP
(A) Overview of the proteolytic products of APP generated by different cleavage events. The products generated in the amyloidogenic (initial cut by b-secretase)
versus non-amyloidogenic (initial cut by a-secretase) pathway only differ in 16 amino acids (bottom). Mutations are depicted, numbering based on APP770.
(B) APP trafficking and processing. APP is synthesized in the ER (a) and trafficked via the TGN (b) to the PM (c) or endosomes (d). Full-length APP can be en-
docytosed from the PM (1) or cleaved by the a-secretase (2) to release sAPPa in the extracellular environment as well as generating C83 that is also endocytosed.
In the EE, full-length APP is cut by the b-secretase generating C99 and soluble APPb (3). Full-length APP and soluble APP fragments generated in the endosome
might be recycled to the PM via recycling endosomes (RE) (4) or can be trafficked toward late endosomes (LEs) (5). In the LEs, these fragments can subsequently
be sorted toward the TGN (6), exocytosed (7), or further trafficked to the lysosome for degradation (8). Cutting of C99 and C83 by the g-secretase might occur in
the TGN, the LE, or in both compartments, therefore possibly releasing Ab and P3 either via the secretory pathway or via exocytosis. Cutting by the g-secretase
also releases the AICD that can translocate to the nucleus (9).
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et al., 2011). Specifically, while APP is internalized by clathrin-
dependent endocytosis, BACE1 is reported to be delivered to
endosomes in an ADP ribosylation factor 6 (ARF6)-dependent
manner (Sannerud et al., 2011). pH at the PM (z7.5) is not
optimal for BACE1, and therefore, BACE1 cleaves APP only
after internalization in the more acidic environment (optimum
z4.5–5.5) (Kalvodova et al., 2005; Vassar et al., 1999) of the
endocytic system. Cutting of APP by BACE1 in endosomes
releases sAPPb in the endosomal lumen, which would most
likely target sAPPb for degradation in the lysosome. However,
secreted sAPPb can be found in cerebrospinal fluid (CSF) (Do-
browolska et al., 2014) and can be secreted by neurons indi-
cating that sAPPb might be additionally generated at the PM or
sorted to the secretory trans-Golgi network (TGN). Alternatively,
sAPPb could be exocytosed from lysosomes or sorted into recy-506 Developmental Cell 32, February 23, 2015 ª2015 Elsevier Inc.cling endosomes (Figure 3). Sorting into recycling endosomes,
however, would presumably require a transmembrane intralumi-
nal sAPPb receptor that interacts with sorting complexes to
direct sAPPb into recycling endosomes. A possible candidate
might be the p75 neurotrophin receptor, which has been shown
to interact with sAPPb (Hasebe et al., 2013) and is recycled via
recycling endosomes (Bronfman and Fainzilber, 2004). Frag-
ments generated by a- or b-cleavage (non-amyloidogenic versus
amyloidogenic) only differ by 16 amino acids, yet only amyloido-
genic processing is thought to lead to AD pathology. In addition
to major cleavage of APP at position 671, b-cleavage can also
occur at less characterized b1 site (APP 681) closer to the
a-cleavage site (Vassar et al., 1999).
After a- or b-cleavage, the resulting membrane associated
C-terminal fragments (respectively, aCTF/C83 or bCTF/C99)
are subsequently cleaved in the transmembrane domain by a
Developmental Cell
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dent on the initial a or b cut) and an APP intracellular domain
(AICD). The exact cut generated by the g-secretase complex
varies, and Ab peptides ranging from 34–50 amino acids have
been identified (Kummer and Heneka, 2014). Around 90% of
all Ab fragments generated are Ab40, but a smaller fraction is
the more fibrillogenic or oligomerization-prone Ab42 and Ab43
peptides found in amyloid plaques (Sisodia and St George-Hys-
lop, 2002). The function, toxicity, and aggregation properties of
Ab have been extensively discussed elsewhere (LaFerla et al.,
2007; Puzzo and Arancio, 2013) and so are not discussed further
here. In comparison to Ab, P3 is generally considered nonamy-
loidgenic, but there are reports that this fragment is found in
preamyloid deposits in Down syndrome (Lalowski et al., 1996)
and can be neurotoxic (Wei et al., 2002).
Considerable work has been conducted to try and locate the
intracellular site where g-secretase cutting of APP occurs. This
issue continues to be controversial with experiments suggesting
that g-secretase cleaves the APP CTF either in the late endo-
some/lysosomal (LE) compartment (Takahashi et al., 2002; Vieira
et al., 2010) or in the TGN (Choy et al., 2012). A sampling of
key observations includes the following: (1) Ab generated by g-
secretase activity has been observed to accumulate in LE (Taka-
hashi et al., 2002), and inhibition of y-secretase activity results in
the accumulation of C99 in EEs (Kaether et al., 2006). (2) Inhibi-
tion of endocytic function decreases Ab generation (Haass
et al., 1992; Koo andSquazzo, 1994) (although such experiments
cannot differentiate TGN versus lysosomal processing of APP,
as both lysosomal biogenesis and endosome-to-TGN sorted
are downstream of these blocks) (Figure 3). (3) APP CTFs and
g-secretase can interact in the TGN (Xia et al., 2000), and block-
ing retrograde transport of APP from endosomes to the TGN de-
creases APP processing (Choy et al., 2012) while increased TGN
sorting by stabilization of the retromer sorting complex has been
shown to decreaseAb generation (Mecozzi et al., 2014). Interest-
ingly, however, total C99 levels were also lowered, indicating
that stabilization of the retromer inhibits Ab generation in an
earlier step such as APP cleavage by BACE1. In line with this
interpretation, BACE1 is also sorted to the TGN by the retromer
complex (Cuartero et al., 2012; Okada et al., 2010), indicating
that the reduction of APP processing by retromer stabilization
is likely due to decreased BACE1 levels in EEs (and not due to
decreased APP/g-secretase interactions in the TGN). Clearly,
more work is required to establish whether Ab is generated in en-
dosomes, the TGN, or both. An important consideration may be
that g-secretase cleavage of APP CTFs in LE versus TGN could
affect the exact g-secretase cut site and influence the size of Ab
generated (40 versus 42, for example). This could be further
regulated by APP-interacting proteins such as SorlA (Willnow
and Andersen, 2013) and BRI2 (Tamayev et al., 2012), which
might sort CTFs away from the g-secretase complex.
It is important to understand in which specific organelle APP
CTFs are cleaved, as it has an implication for pathways of Ab
secretion. Cutting in the TGN would allow the exit of Ab in the
constitutive released secretory pool offering Ab an easy way
out of the cell and into extracellular plaques. Cutting in the LE
would release Ab in the acidic lumen of the organelle where
one would think that it is likely to be degraded. To secrete Ab
in the latter case, LE exocytosis has to occur before Ab isdegraded (Li et al., 2012; Rajendran et al., 2006). In addition to
the release of Ab and P3, cutting by the g-secretase also re-
leases AICD from the membrane. AICD has been suggested to
translocate to the nucleus where it might act as a transcription
factor (Konietzko, 2012; Pardossi-Piquard and Checler, 2012).
Importantly, much of the research on APP trafficking has been
done in non-neuronal cells, and studies in neurons are limited.
APP trafficking in neurons may be more complex, as these cells
are highly polarized. In neurons, APP can be found in both pre-
synaptic and postsynaptic compartments (DeBoer et al., 2014;
Yamazaki et al., 1995), where APP processing can be regulated
by synaptic activity (Kamenetz et al., 2003). In the Drosophila
mushroom body (a brain structure that shares similarities with
mammalian hippocampus), APPL localizes to the soma and
axons but is excluded from dendrites (Gross et al., 2013). Den-
dritic exclusion of APPL depends on endocytosis and binding
of the endocytic YENPTY motif in APPL to X11/Mint (Figure 2)
(Gross et al., 2013), which acts in endocytosis and the TGN.
Another outstanding issue concerns the neuronal compart-
ment in which APP to Ab processing occurs. Both b- and g-sec-
retase can be found in axons and somatodendritic compart-
ments (DeBoer et al., 2014; Sannerud et al., 2011), and both
can be found in vesicles that also contain APP and kinesin-1 (Al-
menar-Queralt et al., 2014; Kamal et al., 2001). Co-localization of
these components in the somatodendritic compartment may be
regulated by synaptic activity (Das et al., 2013). In this context,
an initial report using high-level overexpression suggested that
axonal targeting of APP depends on the APP ectodomain and
Ab sequence, with deletion of this domain resulting in dendritic
sorting (Tienari et al., 1996). Subsequent work (Gunawardena
and Goldstein, 2001) came to a different conclusion and sug-
gested that the C terminus of APP directs axonal targeting, indi-
cating that more work is needed to settle this issue. Targeting
of chimeric APP to either the dendrite or axon suggests that Ab
can be generated in both of these compartments (but may be
increased in dendritic compartments) (DeBoer et al., 2014).
Finally, in contrast to a previous report (Lazarov et al., 2005),
recent work directly examined endogenous APPproteolytic frag-
ments secreted from axons in the absence of APP overexpres-
sion and found that Ab can be generated in the somatodendritic
compartment in a pathway that requires somatodendritic endo-
cytosis and processing (Niederst et al., 2014) followed by axonal
transport of Ab fragments.
APP Proteolytic Products: Unique Proteins with
Specialized Functions
Functions of the sAPP Fragments
Following regulated proteolysis, sAPPa and sAPPb are released
to the extracellular environment, where they are implicated in
processes such as cellular growth, synapse formation, and neu-
rite outgrowth. The sAPPa (and sAPPb) fragments can interact
with the p75 neurotrophin receptor to stimulate neurite
outgrowth (Hasebe et al., 2013), and sAPPa has also been re-
ported to reduce spine density in cultured neurons from APP
knockout mice (Tyan et al., 2012). sAPPa also acts as a prolifer-
ation factor for adult neural progenitor cells (Demars et al., 2011).
While sAPPa is considered neuroprotective, sAPPb is consid-
ered a less potent protectant or even harmful for neurons (Chas-
seigneaux and Allinquant, 2012). Early data indicated that afterDevelopmental Cell 32, February 23, 2015 ª2015 Elsevier Inc. 507
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a small N-terminal fragment (N-APP) that binds to death receptor
6 (DR6), thereby inducing neuronal death and axonal pruning (Ni-
kolaev et al., 2009). However, these findings were later revised
by the same group as they showed DR6 binds the E2 domain
of APP (and not the N terminus) (Olsen et al., 2014). In addition,
axonal pruning was similar in BACE1 KO mice neurons, indi-
cating that pruning is b-secretase cleavage independent. These
findings might also indicate that the APP holoprotein is required
for pruning and that generation of sAPPb is actually an inhibitor of
pruning. Indeed, sAPPb (and sAPPa in a less potent manner) can
induce rapid neural differentiation of human embryonic stem
cells, indicating that it is not toxic for neurons per se (Freude
et al., 2011). The presence of sAPPa might actually decrease
sAPPb and Ab production possibly through an interaction with
BACE1 (Obregon et al., 2012). Thus, in line with their secretion
into the extracellular milieu, most data on sAPPs indicate they
might act as signaling molecules regulating interactions that
control (neuronal) growth and proliferation. Finally, in this regard,
there is an intriguing report that sAPPa and sAPPb may be able
to differentially regulate cholesterol synthesis (Wang et al., 2014).
APP C99 and C83: Phospho-Dependent Protein
Interaction Hubs
After cleavage by either the a-secretase or b-secretase, a rela-
tively small transmembrane domain with a C-terminal extension
remains (C-terminal fragment [CTF]) that interacts with several
adaptor and signaling proteins (Figure 2). It is not known whether
these interactions occur exclusively with CTFs or also occur with
full-length APP or AICD. In addition, for most proteins that
interact with the APP CTF, it is unclear whether they can also
interact with the conservedCTFs of APLP1 andAPLP2 (Figure 2).
Sequence differences between these CTFs are often minor
(different residues, but similar residue properties) except for
the loss of a Pin1 binding motif and a change in charge of the
APLP1 CTF compared with CTF from APP and APLP2. The affin-
ity of some interaction partners for APP, APLP1, and APLP2 pep-
tides in vitro (Tamayev et al., 2009) is different, indicating that
these minor sequence differences can significantly alter their in-
dividual interactomes. Many APP CTF interactors are phospho-
tyrosine binding domain (FE65, X11, Dab-1, and JIP-1) or SH2
(Src Homology 2) domain containing proteins that bind APP in
a phosphorylation-dependent manner. In total, APP CTF has
been shown to be phosphorylated on seven phosphorylation
sites (Lee et al., 2003). SH2-domain containing proteins such
as GRB2 and Shc bind to a YENPTY motif in APP, preferentially
when the first tyrosine (Y) in this motif is phosphorylated (Tam-
ayev et al., 2009; Tarr et al., 2002). Binding of the PTB domain
containing DAB1 and JIP1 is actually decreased by this same
phosphorylation (Tamayev et al., 2009). The phosphorylation
status of APP may be involved in pathogenesis of AD as
Tyr757 (or 682 for APP695) has been found to be more phos-
phorylated in AD versus control patients (Russo et al., 2001),
and mutation of Tyr757 results in more a- versus b-cleavage in
mice (Barbagallo et al., 2010).
APP processing is known to change some of the APP interac-
tome; for example, ShcA preferentially interacts with C99 and
not with C83 (Repetto et al., 2004). ShcA has been implicated
in the generation of signaling cascades by activation of MAPK
(Tamayev et al., 2009), and the proteolytic processing of APP508 Developmental Cell 32, February 23, 2015 ª2015 Elsevier Inc.might therefore regulate activation of these proteins and sig-
naling pathways. Another interesting phosphorylation site in
the APP C terminus is Thr743 (688 in APP695). This phosphory-
lation site is directly followed by a Proline, creating a recognition
site for the prolyl isomerase Pin1 (Pastorino et al., 2006). Pin1
can change protein conformation by conversion of cis or trans
conformations of pSer/Thr-Pro bonds (Stukenberg and Kirsch-
ner, 2001), and this phosphorylation-dependent conformational
change might act as a switch to control APP binding to diverse
interactors proteins. For example, FE65 binds to the YENPTY
motif of APP (Figure 2), and binding of FE65 is inhibited by phos-
phorylation of Thr743 at the upstream Pin1 site, while binding of
interactor proteins such as X11-like and Dab1 is not altered
(Ando et al., 2001). Phosphorylation of APP Tyr682 (within the
YENPTY motif) also inhibits FE65 binding (Zhou et al., 2009).
APP C99, but not C83, is preferentially phosphorylated on
Thr743 (Lee et al., 2003), and Pin1 binds C99 but not full-length
APP nor C83, indicating that differential APP cleavage controls
specific downstream events (Akiyama et al., 2005). One such
event might be signaling through the Wnt-PNP receptor com-
plex (Soldano et al., 2013). C99 interacts with multiple proteins
of this complex (Vangl2, Frizzeld, and Frizzeld5) that regulate
cellular polarity and axonal outgrowth, but whether this is phos-
pho dependent has not been tested (Soldano et al., 2013). In
addition to adaptor and signaling proteins, APP CTFs are also
implicated in interactions with motor proteins such as kinesin,
myosin, and dynein (Cottrell et al., 2005; Goldstein, 2012),
thereby possibly controlling their own transport (Rodrigues
et al., 2012). For example, kinesin-1 localizes to APP-positive
axonal vesicles (Szpankowski et al., 2012), and kinesin-1 may
interact with APP either directly or indirectly via JIP1 (Chiba
et al., 2014; Goldstein, 2012; Kamal et al., 2001; 2000; Lazarov
et al., 2005). Intriguingly, striking evidence has been reported
that JIP1 can directly control anterograde or retrograde direc-
tions of APP transport by controlling the activities of kinesin-1
and dynein (Fu and Holzbaur, 2013). It has also been argued
that APP is required for kinesin-mediated axonal transport of
vesicular compartments containing BACE1 and presenilin-1 (Al-
menar-Queralt et al., 2014; Goldstein, 2012; Kamal et al., 2001;
Rodrigues et al., 2012). Although originally debated (for details,
see Goldstein, 2012), much data now indicate that APP and ki-
nesin-1 interact directly or indirectly in addition to interactions
with Jip1B or calsyntenin in a process that brings multiple
proteins together in a higher order complex that could regulate
molecular motor behavior (Fu and Holzbaur, 2013; Kamal et al.,
2000; Vagnoni et al., 2012). Interestingly, axonopathy and trans-
port defects can be seen in mouse models of AD a year before
any other disease-related pathology (Salehi et al., 2006; Stokin
et al., 2005). Another important clue to the importance of the
APP CTFs in disease development is the observation that muta-
tions in the APP shielding protein BRI2 lead to dementia and in-
hibition of b-secretase (CTF-generation), but not g-secretase
(Ab generation), can rescue memory in some mouse models
(Tamayev et al., 2012). In conclusion, much data are pointing
to an important role of the CTF fragments of APP in these
signaling, sorting, and traffic events, but more research is
required to understand the dependence of these processes
on initial a- or b-cleavage and the role that g-secretase has in
terminating these processes.
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Mutations in 18 of the 770 amino acids of APP give rise to FAD.
Most of these mutations are dominant single amino acid substi-
tutions in different combinations (for example, both D678H and
D678N are pathogenic), and over 30 pathogenic mutations are
known. So far, only one mutation (A673T) has been reported to
protect against AD with high penetrance (Figure 4) (Jonsson
et al., 2012). A large fraction of published studies focuses on
the effects of overexpressedWT ormutant APP and generally fo-
cuses on potential contributions of APP processing to Abwithout
placing comparable attention on the behavior of other fragments
of APP that are produced in equimolar amounts. In this context,
the absence of comparably large numbers of studies of the
effects of FAD mutations on the normal biology and behavior
of APP is a significant absence that is in need of correction. In
fact, while virtually every FAD mutation causes changes in pro-
cessing, it may also change trafficking and signaling pathways
in the neuron in processes that have not yet been specifically
evaluated. Most FAD mutations are close to a-, b-, and g-secre-
tase cleavage motifs, thereby directly affecting the proteolytic
processing of APP.
For example, a group of six mutations close to the g-secre-
tase cutting region are thought to give rise to longer, more fibril-
logenic Ab fragments, as do mutations in residues at the end
of the TM domain (L723 and K724). On the other hand, a
mutation adjacent to the a-secretase site (K687N) makes this
particular APP mutant protein a poor a-secretase substrate
(Citron et al., 1992; Kaden et al., 2012). A mutation in the b0-
cleavage site (E682E) also shifts cleavage to the b-site in-
creasing Ab (Zhou et al., 2011). The APP Swedish mutation
(K670NM671NL) (adjacent to the b-secretase site) has been
shown to make this APP mutant a better BACE-1 substrate,
thereby increasing b-secretase cleavage and enhancing C99
and Ab production (Citron et al., 1992). This effect is specific
for a change of Methionine (M) to Leucine (L) as a change in
Methionine to any other amino acids actually decreases Ab
generation (Citron et al., 1995). The importance of the specific
amino acid substitution is further illustrated by mutations in
A637. While mutations of this residue to Threonine (T) mutation
are protective, homozygous mutations to a Valine (V) are path-
ogenic (Di Fede et al., 2009). Neurons expressing an APP A637T
construct showed decreased b-processing and a less fibro-
genic Ab fragment (Benilova et al., 2014). Although most FAD
mutations cause increased Ab levels, it is not necessarily the
case that this is the only cause for disease. For example, the
full-length APP Swedish mutant APP is a very poor FE65 inter-
actor (Zambrano et al., 1997) and interferes with axonal trans-
port (Rodrigues et al., 2012). In addition, other less studied
pathogenic mutations such as D678 are not near cleavage sites,
and it is unclear how these mutations lead to disease (Lan et al.,
2014; Wakutani et al., 2004). A group of mutations outside
cleavage sites is A692/E693/D694 located in a LVFFAED motif.
This motif acts to inhibit g-secretase activity, but an A692 to G
(Flemish mutant) mutation decreases the inhibitory effect of this
sequence, thereby increasing Ab production (Tian et al., 2010).
Interestingly, this LVFFAED motif is also involved in cholesterol
binding, possibly contributing to pathology (Figure 4) (Barrett
et al., 2012; Tang et al., 2014). We note that in addition to
altering processing, FAD mutations may also alter sorting path-ways simultaneously, with unknown consequences at present
on signaling originating at endosomal and other vesicular inter-
mediates (also see below).
Duplication of the APP gene such as in Down syndrome and
FAD or activating mutations in the APP promoter gives rise
to modest increases of APP levels (Theuns et al., 2006), and
most investigators accept that Ab is the culprit. However,
such modest increases in APP have also been shown to poi-
son processes regulated by other fragments such as axonal
transport and long-distance signaling (in models and patients)
(Cataldo et al., 2004; Israel et al., 2012; Rodrigues et al., 2012;
Salehi et al., 2006). These dosage changes can also induce
endosomal swelling. Neurons are particularly vulnerable to
disruptions in axonal transport and endosomal function
(Neefjes and van der Kant, 2014), explaining why the brain
might be the first organ effected by these changes. From the
sparse data on FAD mutations, we can conclude that specific
mutations are likely to have specific downstream effects.
Although all of these mutations result in AD, not all of these
AD mutations are the same. Drug development, and eventually
drug treatment, may need to be individualized for specific APP
mutations based on a better understanding of their individual
downstream affects. The use of induced pluripotent stem
cell (IPS)-derived neuronal patient lines and AD mutations
introduced by genome editing in isogenic neuronal IPS lines
(Israel et al., 2012; Kondo et al., 2013; Muratore et al., 2014;
Shi et al., 2012; Woodruff et al., 2013; Yagi et al., 2011) could
therefore act as a valuable new tool for future studies of these
different ADs.
Conclusions
While the sheer numbers of investigations of APP function are in
some sense overwhelming, some consistencies emerge. In
particular, APP seems to modulate interactions with intracellular
signaling systems implicated in the growth of axonal and den-
dritic processes and in the support of a variety of functions
involved in synaptic maintenance. Such signaling may depend
on regulated proteolysis of APP to a variety of fragments that
regulate normal intracellular trafficking as well as neuronal
migration in early embryogenesis. In adults, APP and APP frag-
ments might function as sensors that respond to cellular activity
or damage by controlling cholesterol homeostasis, delivery of
vesicular carriers, cellular growth, and proliferation. These activ-
ities are particularly important in large neurons in which APPmay
act as a long-distance sensor transducing information about
distant functions and synaptic activity to the cell body. While
Ab aggregation in disease pathology has been a major focus in
the field, it is becoming apparent that we should place equivalent
focus on endogenous functions of APP and APP fragments. For
example, what is the role of sAPP and APP CTF fragments in
normal neuronal functioning, and why is the generation of these
different fragments altered in AD? How do these fragments
or their interacting proteins contribute to pathology? Is the gen-
eration of these fragments causative or merely a measure of
altered processes upstream of APP processing such as synaptic
activity, cholesterol metabolism, or axonal trafficking defects?
If causative, can we design pharmaceutical approaches that
alter the generation or interactions of these specific fragments
without affecting positive neurotropic effects of APP? WhileDevelopmental Cell 32, February 23, 2015 ª2015 Elsevier Inc. 509
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Figure 4. A Detailed Overview of APP Residues Involved in FAD and Cholesterol Binding
Schematic representation of amino acids in APP, numbering based on APP770. Secretase cleavage sites are indicated (with B’ is aminor b-secretase site). The g-
secretase can cleave at multiple positions, giving rise to Ab fragments with different lengths, as shown in the left. An extracellular domain in the ectodomain of
APP—adjacent to the transmembrane domain—was recently shown to fold back into the PMand to be important for cholesterol interactions.Membrane insertion
has also been shown for the extreme C terminus of APP. The PM is in gray.
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Reviewthis is a major challenge, new molecular and cellular tools that
are becoming available may help to solve the important question
of APP function and how apparently modest alterations in510 Developmental Cell 32, February 23, 2015 ª2015 Elsevier Inc.behavior of mutant APP over long periods of time are involved
in changes in neuronal maintenance, brain viability, and AD initi-
ation and progression.
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